Search Results 11-20 of 51 for USDT正规交易【电报：@xottc67788】正规平台安全有保障

  1. A Study to Evaluate the Effectiveness, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera - Mayo Clinic

    The purpose of this study is to evaluate the safety and effectiveness of idasanutlin monotherapy in participants with hydroxyurea (HU)-resistant/intolerant ...

  2. A Study to Evaluate Gemcitabine and MK-3475 (Pembrolizumab) to Treat Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mayo Clinic

    The purpose of this study is to assess the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose ...

  3. A Study to Evaluate the Safety and Effectiveness of TT-00420 in Adults with Advanced Cholangiocarcinoma - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  4. A Study of Response, Survival, Safety, and Tolerability of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer - Mayo Clinic

    The purpose of this study is to evaluate response, survival, safety, and tolerability of treatment with lenvatinib for patients who have anaplastic thyroid ...

  5. First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors - Mayo Clinic

    TP-0903 is a novel oral inhibitor that targets AXL kinase. Preclinical studies have shown promising antitumor activity of TP-0903 as a single agent against a ...

  6. A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ - Mayo Clinic

    H2NVAC is a vaccine designed to stimulate specialized white blood cells in hopes of increasing immune response and protecting against breast cancer.

  7. Study of ASTX727 vs IV Decitabine in MDS and CMML - Mayo Clinic

    After completion of PK studies during the first 2 treatment cycles, subjects will continue to receive treatment with ASTX727 from Cycle 3 onward (in 28-day ...

  8. https://www.mayoclinic.org/chinese_condition_consolidated_concepts.xml

  9. https://www.mayoclinic.org/spanish_condition_consolidated_concepts.xml

  10. A Study of ASTX660 Alone or Combined with ASTX727 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) - Mayo Clinic

    About this study. The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination ...